FEB 27, 2017 6:05 AM PST

Study Links Immunotherapy Response To Gut Microbiome

WRITTEN BY: Xuan Pham

Immunotherapy, the technique of using the immune system to fight off disease, is one of the most promising avenues for anticancer treatments. However, even with the help of the immune system, not all immunotherapy drugs produce the same response across patients. This variability has been attributed to genetic differences between individuals. And now, a new study reports another cause for drug variability: the bacteria residing in patients’ guts.

In studying the melanoma patients’ variable response to an immunotherapy, researchers at the University of Texas MD Anderson Cancer Center identified a crucial link with the patients’ gut microbiome. Specifically, those with a more diverse microbiome showed better response to the immunotherapy, which led to better outcomes.

The immunotherapy under investigation involves PD-1 immune checkpoint inhibitors. This drug works by blocking a programmed death receptor in the body’s immune cells, allowing these cells to perk up longer and attack the tumor. But while effective, it doesn’t work for everybody. “Anti-PD1 immunotherapy is effective for many, but not all, melanoma patients and responses aren't always durable,” said Jennifer Wargo, an associate professor of Surgical Oncology, and the study’s senior author.

Wargo and her team analyzed the microbiome of 233 melanoma patients through oral swab and fecal samples. They identified a subset of patients who received anti-PD-1 therapy, and classified that group to those who responded and those who didn’t.

This revealed a striking pattern about the microbiome. In particular, Clostridiales bacteria were found in high abundance in the guts of responders. Furthermore, these people had a more diverse range of bacteria. By contrast, those who didn’t respond to immunotherapy had more uniform bacteria species, including a higher concentration of Bacteroidales bacteria.

“Our findings point to two potential impacts from additional research – analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment,” said Wargo, who is also the co-leader of the Melanoma Moon Shot program.

So far, the results represent the first link between immunotherapy response and microbiome influence. However, to establish causal relationship between these two factors would require careful clinical trials, which Wargo say will begin later this year. Such studies will provide context as to which bacteria are truly beneficial, and how we can modulate these microorganisms to give patients better outcomes.

Additional sources: MD Anderson Cancer Center

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 07, 2020
Cancer
Beyond the eye: improving melanoma detection
OCT 07, 2020
Beyond the eye: improving melanoma detection
Research from UC San Francisco reports that it is possible to use genomic methods to detect skin damage from the sun not ...
OCT 27, 2020
Cancer
Increased muscle mass improves outcomes for colorectal cancer surgery
OCT 27, 2020
Increased muscle mass improves outcomes for colorectal cancer surgery
New research published in JAMA Surgery reports a new way to prepare for surgery: sit-ups. According to the findings ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 15, 2020
Genetics & Genomics
Novel Cancer-Driving Genes are Discovered
NOV 15, 2020
Novel Cancer-Driving Genes are Discovered
Cells have to be able to divide so new ones can replenish cells that get worn out, dysfunctional, or that accumulate dam ...
NOV 14, 2020
Cancer
New intravenous anti-cancer therapy crosses blood-brain barrier
NOV 14, 2020
New intravenous anti-cancer therapy crosses blood-brain barrier
New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is abl ...
NOV 20, 2020
Cancer
How does tissue geometry influence cancer cellular migration?
NOV 20, 2020
How does tissue geometry influence cancer cellular migration?
A team of researchers led by UC Santa Barbara's Distinguished Professor Denise Montell has recently published new fi ...
Loading Comments...